Not Yet RecruitingNot Applicable

Impact of a One-Week Discontinuation of Semaglutide on Gastric Retention and Endoscopic Mucosal Visibility Scores

China418 participantsStarted 2025-09-15

Plain-language summary

A prospective, single-center, observational study to compare the risk of gastric retention and endoscopic mucosal visibility between the exposure group (one-week discontinuation of semaglutide before EGD) and non-exposure group (no semaglutide use before EGD)

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Subjects who have either: (i) been on long-term semaglutide therapy (≥4 weeks, any dosage) and discontinued use for one week prior to gastroscopy (with the last dose 8-14 days before the procedure), or(ii) never used semaglutide.
✓. For patients with diabetes mellitus (DM), HbA1c \< 9% to ensure adequate glycemic control.
✓. Age ≥ 18 years, with no restriction on sex.
✓. American Society of Anesthesiologists (ASA) physical status classification I-II.
✓. Fasting for at least 8 hours and no water intake for at least 4 hours before gastroscopy.
✓. Undergoing painless (sedated) endoscopy.

Exclusion criteria

✕. History of hiatal hernia or any previous gastric surgery (including gastrectomy, Roux-en-Y gastric bypass, etc.).
✕. Pregnancy.
✕. Medically unfit for gastrointestinal endoscopy.
✕. Deemed unsuitable for participation at the discretion of the investigators.

What they're measuring

Rate of gastric retention

Timeframe: immediately after the esophagogastroduodenoscopy

Trial details

NCT IDNCT07152756

SponsorFudan University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2028-09-15

Contact for this trial

Danian Ji, M.D.

+86-18019094606 arctg4@163.com

View on ClinicalTrials.gov More Gastric Retention trials